Evogene (NASDAQ:EVGN) Stock Passes Below 200 Day Moving Average – Here’s What Happened

Evogene Ltd. (NASDAQ:EVGN) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.11 and traded as low as $0.7423. Evogene shares last traded at $0.8090, with a volume of 1,080,831 shares trading hands.

Evogene Stock Performance

The company has a market cap of $4.34 million, a P/E ratio of -0.69 and a beta of 1.36. The firm’s fifty day moving average is $0.98 and its two-hundred day moving average is $1.11.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.35). Evogene had a negative net margin of 214.57% and a negative return on equity of 121.44%. The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.28 million.

Institutional Trading of Evogene

Several institutional investors and hedge funds have recently added to or reduced their stakes in EVGN. XTX Topco Ltd bought a new position in Evogene in the 4th quarter worth approximately $25,000. Jane Street Group LLC grew its holdings in Evogene by 58.0% during the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,387 shares in the last quarter. Finally, Citadel Advisors LLC raised its position in shares of Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares during the last quarter. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.